Positive inotropic medications

35,403views

Positive inotropic medications

ETP Cardiovascular System

ETP Cardiovascular System

Introduction to the cardiovascular system
Anatomy of the heart
Anatomy of the coronary circulation
Anatomy clinical correlates: Heart
Anatomy of the superior mediastinum
Anatomy of the inferior mediastinum
Anatomy clinical correlates: Mediastinum
Development of the cardiovascular system
Fetal circulation
Cardiac muscle histology
Artery and vein histology
Arteriole, venule and capillary histology
Cardiovascular system anatomy and physiology
Lymphatic system anatomy and physiology
Coronary circulation
Blood pressure, blood flow, and resistance
Pressures in the cardiovascular system
Laminar flow and Reynolds number
Resistance to blood flow
Compliance of blood vessels
Control of blood flow circulation
Microcirculation and Starling forces
Measuring cardiac output (Fick principle)
Stroke volume, ejection fraction, and cardiac output
Cardiac contractility
Frank-Starling relationship
Cardiac preload
Cardiac afterload
Law of Laplace
Cardiac and vascular function curves
Altering cardiac and vascular function curves
Cardiac cycle
Cardiac work
Pressure-volume loops
Changes in pressure-volume loops
Physiological changes during exercise
Cardiovascular changes during hemorrhage
Cardiovascular changes during postural change
Normal heart sounds
Abnormal heart sounds
Action potentials in myocytes
Action potentials in pacemaker cells
Excitability and refractory periods
Cardiac excitation-contraction coupling
Cardiac conduction system
Cardiac conduction velocity
ECG basics
ECG rate and rhythm
ECG intervals
ECG QRS transition
ECG axis
ECG normal sinus rhythm
ECG cardiac infarction and ischemia
ECG cardiac hypertrophy and enlargement
Baroreceptors
Chemoreceptors
Renin-angiotensin-aldosterone system
Arterial disease
Angina pectoris
Stable angina
Unstable angina
Myocardial infarction
Prinzmetal angina
Coronary steal syndrome
Peripheral artery disease
Subclavian steal syndrome
Aneurysms
Aortic dissection
Vasculitis
Behcet's disease
Kawasaki disease
Hypertension
Hypertensive emergency
Renal artery stenosis
Coarctation of the aorta
Cushing syndrome
Conn syndrome
Pheochromocytoma
Polycystic kidney disease
Hypotension
Orthostatic hypotension
Abetalipoproteinemia
Familial hypercholesterolemia
Hypertriglyceridemia
Hyperlipidemia
Chronic venous insufficiency
Thrombophlebitis
Deep vein thrombosis
Lymphedema
Lymphangioma
Shock
Vascular tumors
Human herpesvirus 8 (Kaposi sarcoma)
Angiosarcomas
Persistent truncus arteriosus
Transposition of the great vessels
Total anomalous pulmonary venous return
Tetralogy of Fallot
Hypoplastic left heart syndrome
Patent ductus arteriosus
Ventricular septal defect
Atrial septal defect
Atrial flutter
Atrial fibrillation
Premature atrial contraction
Atrioventricular nodal reentrant tachycardia (AVNRT)
Wolff-Parkinson-White syndrome
Ventricular tachycardia
Brugada syndrome
Premature ventricular contraction
Long QT syndrome and Torsade de pointes
Ventricular fibrillation
Atrioventricular block
Bundle branch block
Pulseless electrical activity
Tricuspid valve disease
Pulmonary valve disease
Mitral valve disease
Aortic valve disease
Dilated cardiomyopathy
Restrictive cardiomyopathy
Hypertrophic cardiomyopathy
Heart failure
Cor pulmonale
Endocarditis
Myocarditis
Rheumatic heart disease
Pericarditis and pericardial effusion
Cardiac tamponade
Dressler syndrome
Cardiac tumors
Acyanotic congenital heart defects: Pathology review
Cyanotic congenital heart defects: Pathology review
Atherosclerosis and arteriosclerosis: Pathology review
Coronary artery disease: Pathology review
Peripheral artery disease: Pathology review
Valvular heart disease: Pathology review
Cardiomyopathies: Pathology review
Heart failure: Pathology review
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Aortic dissections and aneurysms: Pathology review
Pericardial disease: Pathology review
Endocarditis: Pathology review
Hypertension: Pathology review
Shock: Pathology review
Vasculitis: Pathology review
Cardiac and vascular tumors: Pathology review
Dyslipidemias: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Cardiomyopathies: Clinical
Congenital heart defects: Clinical
Valvular heart disease: Clinical
Infective endocarditis: Clinical
Pericardial disease: Clinical
Chest trauma: Clinical
Hypertension: Clinical
Aortic aneurysms and dissections: Clinical
Peripheral vascular disease: Clinical
Heart failure: Clinical
Coronary artery disease: Clinical
Pulmonary hypertension
Raynaud phenomenon
Fascia, vessels and nerves of the upper limb
Vessels and nerves of the forearm
Vessels and nerves of the hand
Anatomy of the abdominal viscera: Blood supply of the foregut, midgut and hindgut
Fascia, vessels and nerves of the lower limb
Vessels and nerves of the gluteal region and posterior thigh
Anatomy of the popliteal fossa
Ventilation
Ventilation-perfusion ratios and V/Q mismatch
Gas exchange in the lungs, blood and tissues
Oxygen binding capacity and oxygen content
Oxygen-hemoglobin dissociation curve
Carbon dioxide transport in blood
Trypanosoma cruzi (Chagas disease)
Yellow fever virus
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Arteriovenous malformation
Cerebral circulation

Transcript

Watch video only

Positive inotropic medications, as their name implies, are a diverse group of medications that increase the strength of heart muscle contraction.

As a result, they increase the stroke volume and thus, the cardiac output.

Positive inotropic medications include cardiac glycosides, like digoxin; beta agonists, like dobutamine; and phosphodiesterase inhibitors, like milrinone.

They are used in conditions where the heart can’t pump enough blood to the body’s tissues, like in systolic heart failure.

Alright, the heart needs to squeeze out a certain volume of blood each minute, called the cardiac output, which can be rephrased as the heart rate multiplied by the stroke volume, which is the volume of blood squeezed out with each heartbeat.

Okay, now the stroke volume depends on the preload, or the amount of blood that returns to the heart; the afterload, or peripheral resistance; and the strength of the contraction, or contractility, of the cardiac muscle.

Now, muscle contraction is initiated with an action potential which modifies receptors allowing calcium ions to flow from the sarcoplasmic reticulum into the sarcoplasm.

This allows myosin heads to bind to the actin.

These two proteins are ultimately responsible for cell contraction.

In order for a muscle to relax, calcium ions must be pumped back into the sarcoplasmic reticulum.

When the frequency of stimulation is increased, more calcium ions accumulate in the sarcoplasm, and the strength of contraction increases.

Alright, now there are conditions in which the strength of the heart’s contraction is impaired, and the heart can’t pump out enough blood to meet the body’s demands, this is called heart failure.

For example, in systolic heart failure, the heart’s ventricles can’t pump blood hard enough during systole, so as a result, the cardiac output decreases.

This is typically due to some kind of damage to the myocardium so the heart can’t contract as forcefully or pump blood as efficiently.

Ischemic heart disease caused by coronary artery atherosclerosis, or plaque buildup, is the most common cause.

Alright, now, positive inotropic medications can increase the strength of heart contraction and can be used for the treatment of these conditions.

So let’s start with the cardiac glycosides which are also known as digitalis glycosides because they’re derived from the plant digitalis.

The prototype cardiac glycoside is digoxin. Digoxin acts by inhibiting the sodium/potassium ATPase pump, at the cell membrane of the cardiomyocyte.

Na+/K+ ATPase normally moves 2 potassium ions into the cell for every 3 sodium ions out.

Now, with digoxin, potassium can’t enter the cell and sodium can’t leave it, resulting in an increase in sodium inside the cell.

But sodium finds another way to get out of the cell via the sodium/calcium exchanger that moves calcium into the cell and sodium out.

Once this extracellular calcium gets inside, it binds to receptors on the sarcoplasmic reticulum.

This releases even more calcium into the cell via a process called calcium-induced calcium release.

Now, calcium increases interaction of the two contractile proteins, actin and myosin, and ultimately improves cardiomyocyte contractility and cardiac function to reduce the symptoms of chronic heart failure.

Digoxin also exerts parasympathetic effects by inhibiting the Na+/K+ ATPase found at the cell membrane of vagal neurons leading to a decrease in heart rate.

But because parasympathetic innervation is much richer in the atria, these effects mainly involve the atria and so digoxin can also be used for the treatment of atrial arrhythmias, such as atrial flutter and atrial fibrillation.

Notice that digoxin is not considered first line treatment for heart failure or atrial arrhythmias because it has a narrow therapeutic window and it doesn’t reduce mortality in individuals with heart failure.

However, it’s a useful agent in individuals with chronic heart failure and concomitant atrial arrhythmia.

Now the narrow therapeutic window means it’s easy to overdose and digoxin has some nasty side effects.

The more common side effects include gastrointestinal disturbances such as nausea, vomiting, anorexia and diarrhea.

It could also cause electrocardiographic abnormalities, such as T wave changes, a short QT interval, ST depression, and arrhythmias.

The most common type of arrhythmia is premature ventricular contractions, although any type of arrhythmia can occur.

Also, by stimulating the vagus nerve, digoxin can lead to bradycardia and heart block.

Another side effect of digoxin is hyperkalemia, or elevated potassium levels, because digoxin doesn’t permit the potassium to enter the cells and so it accumulates in the circulation.

Now, other side effects include neurologic symptoms such as confusion, disorientation, and visual disturbances like xanthopsia, which is when objects appear yellow.

Alright, now factors that predispose to toxicity include electrolyte abnormalities like hypokalemia, or low potassium levels, hypomagnesemia, or low magnesium levels, and hypercalcemia, or elevated calcium levels.

Okay, now digoxin is excreted through the kidneys, so serum levels can increase if there’s renal dysfunction.

Key Takeaways

Positive inotropic medications are medications that increase the force of muscle contraction of the heart, resulting in an increased cardiac output. Examples of positive inotropic medications include digoxin, dobutamine, and milrinone. These medications are generally used to treat systolic heart failure, cardiogenic shock, and other heart-related conditions.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Digoxin in Heart Failure with a Reduced Ejection Fraction: A Risk Factor or a Risk Marker?" Cardiology (2016)
  5. "Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome" Cochrane Database of Systematic Reviews (2018)
  6. "Treatments targeting inotropy" European Heart Journal (2018)
  7. "Therapeutic achievements of phosphodiesterase inhibitors and the future" European Heart Journal (1989)